Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled trial of lanadelumab in non-histaminergic angioedema with normal C1-inhibitor
jRCT2061210013Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in angioedema comparing Lanadelumab 300 mg SC q2w with Placebo SC q2w (2 arms). Primary endpoint: Number of investigator-confirmed angioedema attacks during treatment period (Day 0–182). Started May 2020; status: completed.
02
Drugs
lanadelumab
03
Conditions
angioedema
Beyond the preview
Go deeper on jRCT2061210013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210013.